Zadavotide guraxetan

PSMA I&T is an effective inhibitor of prostate-specific membrane antigen (PSMA) . PSMA I&T can be used for SPECT/CT imaging and radionuclide studies in triple-negative breast cancer and prostate cancer (PCa) [1][2].

Product Specifications

CAS Number

[2192281-54-0]

Product Name Alternative

PSMA I&T; PNT-2002

UNSPSC

12352203

Target

PSMA

Type

ADC Related

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/psma-i-t.html

Concentration

10mM

Purity

99.86

Solubility

DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C) |H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

IC(C=C1C[C@H](C(N[C@@H](C(N[C@@H](C(O)=O)CCCCNC(CCCCCCC(NCCCC[C@@H](C(O)=O)NC(N[C@H](C(O)=O)CCC(O)=O)=O)=O)=O)=O)CC2=CC=CC=C2)=O)NC(CCC(N3CCN(CCN(CCN(CC3)CC(O)=O)CC(O)=O)CC(O)=O)C(O)=O)=O)=C(C=C1)O

Molecular Formula

C63H92IN11O23

Molecular Weight

1498.37

References & Citations

[1]Chatalic KL, et al. Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent. Theranostics. 2016 Apr 12;6 (6) :849-61.|[2]Amelie Heesch, et al. The prostate-specific membrane antigen holds potential as a vascular target for endogenous radiotherapy with [177Lu]Lu-PSMA-I&T for triple-negative breast cancer. Breast Cancer Res. 2024 Feb 20;26 (1) :30.